3rd Annual idiopathic pulmonary fibrosis (IPF) Summit 2019

3rd Annual IPF Summit 2019 is organized by Hanson Wade and will be held from Aug 27 - 29, 2019 at Sheraton San Diego Hotel & Marina, San Diego, California, United States of America.

The World’s Largest Gathering of IPF Drug Developers
The IPF Summit focuses exclusively on closing the translational gap between preclinical predictability and clinical attrition to accelerate the development of truly curative idiopathic pulmonary fibrosis (IPF) therapeutics.

With the 2019 conference expanding upon an even greater breadth and depth of content, you’ll hear three days of unrivalled scientifically driven and case-study based analysis and discussion, as together leading academia and biopharma advance the IPF drug development frontier.

Last year, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging, share clinical insights, and evaluate better recapitulating disease physiology in vitro exclusively for IPF.

“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!”

Ceders-Sinai Medical Center

Workshop A
Aug 27, 2019
9:00am – 12:00pm
Overlap Between IPF & Other Fibrotic Diseases: Pathophysiology & Target Identification in Fibrosis
Description:
With better screens and better tools giving better outcomes, critically assessing molecular prognostic biomarkers of fibrosis can inform an arsenal of non-invasive techniques and innovate drug development.

This workshop will explore:
• Overlap and relationships between organ-specific pathological fibrosis
• Common pathways to different organ-specific fibrosis; is there a central regulator of fibrosis across several organs that we can target?
• Combination therapy to treat fibrosis; specifically, bi-functional molecules regulating both inflammation and fibrosis.

Workshop B
Aug 27, 2019
12:30pm – 3:30pm
Adding Radiology to the Pulmonary Fibrosis Equation
Description:
Advancements in the application of imaging techniques to inform and enrich clinical trial decisions goes hand-in-hand with the next generation of IPF drug development.

Following on from last IPF Summit’s workshop, continue the conversation on imaging’s capacity to:
• Advance biomarker identification
• Differentially diagnoses patients
• Improve clinical translation

Workshop C
Aug 27, 2019
4:00pm – 7:00pm
Working Meeting of the Prognostic Lung Fibrosis Consortium (PROLIFIC)
Description:
As clinical trial activity gears up, developing well-characterized assays to determine clinical utility and commercial potential of current predictive or prognostic biomarkers is becoming increasingly important.

This expert led meeting will cover:
• Evaluation of additional inflammation markers for the PROLIFIC list
• Update on Clinical Testing Laboratories selection and contracting process
• Execution of the collaboration agreement

Time: 8:00 am to 4:00 pm